Advertisement

Biochemical Loci for Modulation of 5-Fluorouracil Activity

  • Peter V. Danenberg
Part of the Developments in Oncology book series (DION, volume 47)

Abstract

The development of the fluoropyrimidines as anticancer drugs began in 1957 with the publication by Heidelberger of a method for the synthesis of 5-fluorouracil (FU) (1). This compound was soon found to possess significant antitumor activity in both mice (2) and men (3) and today FU and some of its derivatives, notably the deoxyribonucleoside 5-fluoro-2′-deoxyuridine (FdUrd), are extensively used in the treatment of metastatic cancers, singly or in combination with other drugs. In addition to anticancer drugs, the fluoropyrimidines have been used as biochemical tools to study a wide variety of problems in biochemistry and cell biology. As might be expected, a vast literature on fluoropyrimidines has been generated describing studies on their metabolism, mechanism of action, biochemical pharmacology, synthesis of new derivatives, and clinical antitumor activity.

Keywords

Ternary Complex Thymidylate Synthetase Ternary Complex Formation Murine Colonic Adenocarcinoma L1210 Mouse Leukemia Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Duschinsky R, Pleven E, Heidelberger C: The synthesis of 5-fluoropyrimidines. J. Am. Chem. Soc. 79: 4559–4560, 1957.CrossRefGoogle Scholar
  2. 2.
    Heidelberger C, Griesbach L, Montag BJ et al: Studies on fluorinated pyrimidines. II. Effects on transplanted tumors. Cancer Res. 18: 305–317, 1958.Google Scholar
  3. 3.
    Curreri AR, Ansfield FJ, Mclver FA et al: Clinical studies with 5-fluorouracil. Cancer Res. 18: 478–484, 1958.PubMedGoogle Scholar
  4. 4.
    Rutman RJ, Cantarow A, Paschkis KE: Studies in 2-acetyl-aminofluorene carcinogenesis. III. The utilization of uracil-2-14C by preneoplastic rat liver and rat hepatoma. Cancer Res. 14: 119–134, 1954.PubMedGoogle Scholar
  5. 5.
    Heidelberger C, Chaudhuri NK, Danenberg P et al: Fluorinated pyrimidines, a new class of tumor inhibitory compounds. Nature 179: 663–666, 1957.PubMedCrossRefGoogle Scholar
  6. 6.
    Bosch L, Harbens E, Heidelberger C: Studies on fluorinated pyrimidines. V. Effects on nucleic acid metabolism in vitro. Cancer Res. 18: 335–343, 1958.Google Scholar
  7. 7.
    Cohen SS, Flaks JG, Barner HD et al: The mode of action of 5-fluorouracil and its derivatives. Proc. Nat. Acad. Sci. USA 44: 1004–1012, 1958.PubMedCrossRefGoogle Scholar
  8. 8.
    Chaudhuri NK, Montag BJ, Heidelberger C: Studies on fluorinated pyrimidines. III. The metabolism of 5-fluorouracil-2-14C and 5-fluorourotic acid-2-14C in vivo. Cancer Res. 18: 318–328, 1958.PubMedGoogle Scholar
  9. 9.
    Heidelberger C, Danenberg PV, Moran RG: Fluorinated pyrimidines and their nucleosides. Adv. Enzymol. 54: 57–119, 1983.Google Scholar
  10. 10.
    Pham T, Ardalan B, Villacorte D et al: Intracellular PRPP concentration and metabolism as a determinant of 5-fluorouracil response in murine colonic adenocarcinomas. Proc. Am. Assoc. Cancer Res. 22: 30, 1981.Google Scholar
  11. 11.
    Reyes P, Hall TC: Synthesis of 5-fluorouridine-5′-phosphate by a pyrimidine phosphoribosyltransferase of mammalian origin. II. Correlation between the tumor levels of the enzyme and the 5-fluorouracil-promoted increase in survival of tumor-bearing mice. Biochem. Pharmacol. 18: 2587–2590, 1969.Google Scholar
  12. 12.
    Schwartz PM, Dunigan JM, Marsh JC, Handschumacher RE: Allopurinol modification of the toxicity and antitumor activity of 5-fluorouracil. Cancer Res. 40: 1855–1889, 1980.Google Scholar
  13. 13.
    Benz C, Cadman E: Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma HCT-8. Cancer Res. 41: 994–999, 1981.PubMedGoogle Scholar
  14. 14.
    Villacorte D, Ardalan B, Arakawa M et al: In vitro and in vivo effect of glutamine antagonists on PRPP metabolism in P388 leukemia and in murine colonic adenocarcinoma. Proc. Am. Assoc. Cancer Res. 22: 31, 1981.Google Scholar
  15. 15.
    Kahan FM, Hurwitz J: The role of deoxyribonucleic acid in ribonucleic acid synthesis. J. Biol. Chem. 237: 3778–3785, 1962.Google Scholar
  16. 16.
    Kent RJ, Heidelberger C: Fluorinated pyrimidines. XL. The reduction of 5-fluorouridine-5′-diphosphate by ribonucleo-tide reductase. Mol. Pharmacol. 8: 465–475, 1972.Google Scholar
  17. 17.
    Kufe DW, Major PP, Egan EY, Loh E: 5-Fluoro-2′-deoxyuri-dine incorporation into L1210 DNA. J. Biol. Chem. 256: 8885–8888, 1981.PubMedGoogle Scholar
  18. 18.
    Caradonna SJ, Cheng YC: Uracil DNA-glycosylase. Purification and properties of this enzyme isolated from blast cells of acute myelocytic leukemia patients. J. Biol. Chem. 255: 2293–2300, 1980.Google Scholar
  19. 19.
    Blakley RL: The biochemistry of folic acid and related pteridines. American Elsevier, New York, 1969, p. 237.Google Scholar
  20. 20.
    Wilkinson DS, Crumley J: Metabolism of 5-fluorouracil in sensitive and resistant Novikoff hepatoma cells. J. Biol. Chem. 252: 1051–1056, 1977.PubMedGoogle Scholar
  21. 21.
    Wilkinson DS, Pitot HC: Inhibition of ribosomal ribonucleic acid maturation in Novikoff hepatoma cells by 5-fluorouracil and 5-fluorouridine. J. Biol. Chem. 218: 63–68, 1973.Google Scholar
  22. 22.
    Armstrong RD, Takimoto CH, Cadman E: Fluorouracil (FUra) induced alterations of messenger (m) and small nuclear (sm) RNA. Proc. Am. Assoc. Cancer Res. 25: 20, 1984.Google Scholar
  23. 23.
    Santelli G, Valeriote F: In vivo potentiation of 5-fluorouracil cytotoxicity against AKR leukemia by purines, pyrimidines, and their nucleosides and deoxynucleosides. J. Natl. Cancer Inst. 64: 69–72, 1980.PubMedGoogle Scholar
  24. 24.
    Martin DS, Stolfi RL, Spiegelman S: Striking augmentation of the in vivo anticancer activity of 5-fluorouracil by combination with pyrimidine nucleosides: An RNA effect. Proc. Am. Assoc. Cancer Res. 19: 221, 1978.Google Scholar
  25. 25.
    Danenberg PV, Heidelberger C, Mulkins MA, Peterson AR: The incorporation of 5-fluoro-2′-deoxyuridine into DNA of mammalian tumor cells. Biochem. Biophys. Res. Commun. 102: 654–658, 1981.PubMedCrossRefGoogle Scholar
  26. 26.
    Schuetz JD, Wallace HJ, Diasio RB: 5-Fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity. Cancer Res. 44: 1358–1363, 1984.PubMedGoogle Scholar
  27. 27.
    Schuetz JD, Wallace H, Banks W, Diasio RB: Removal of 5-fluorouracil (FU) from DNA induces DNA strand breaks in mouse bone marrow (BM) cells exposed to cytotoxic concentrations of FU. Proc. Am. Assoc. Cancer Res. 25: 21, 1984.Google Scholar
  28. 28.
    Danenberg PV, Lockshin A: Fluorinated pyrimidines as tightbinding inhibitors of thymidylate synthetase. Pharmac. Ther. 13: 69–90, 1981.CrossRefGoogle Scholar
  29. 29.
    Evans RM, Laskin JD, Hakala MT: Assessment of growthlimiting events caused by 5-fluorouracil in mouse cells and in human cells. Cancer Res. 40: 4113–4122, 1980.PubMedGoogle Scholar
  30. 30.
    Laskin JD, Evans RM, Slocum HD et al: Basis for natural variation in sensitivity to 5-fluorouracil in mouse and human cells in culture. Cancer Res. 39: 383–390, 1979.PubMedGoogle Scholar
  31. 31.
    Woodcock TM, Martin DS, Damin LAM et al: Combination clinical trials with thymidine and fluorouracil: A Phase I and clincial pharmacologic evaluation. Cancer 45: 1135–1143, 1980.PubMedCrossRefGoogle Scholar
  32. 32.
    Lockshin A, Danenberg PV: Biochemical factors affecting the tightness of 5-fluorodeoxyuridylate binding to human thymidylate synthetase. Biochem. Pharmacol. 30: 247–257, 1981.PubMedCrossRefGoogle Scholar
  33. 33.
    Klubes P, Connelly K, Cerna I, Mandel HG: Effects of 5-fluorouracil on 5-fluorodeoxyuridine-5′-monophosphate and 2-deoxyuridine-5′-monophosphate pools and DNA synthesis in solid mouse L1210 and rat Walker 256 tumors. Cancer Res. 38: 2325–2331, 1978.PubMedGoogle Scholar
  34. 34.
    Myers CE, Young RC, Johns DG, Chabner BA: Assay of 5-fluorodeoxyuridine-5′-monophosphate and deoxyuridine-5′-mono-phosphate pools following 5-fluorouracil. Cancer Res. 34: 2682–2688, 1974.PubMedGoogle Scholar
  35. 35.
    Moran RG, Spears CP, Heidelberger C: Biochemical determinants of tumor sensitivity to 5-fluorouracil: Ultrasensitive methods for the determination of 5-fluoro-2′-deoxyuridylate, and thymidylate synthetase. Proc. Natl. Acad. Sci. USA 76: 1456–1460, 1979.PubMedCrossRefGoogle Scholar
  36. 36.
    Moran RG, Danenberg PV, Heidelberger C: Therapeutic response of leukemic mice treated with fluorinated pyrimidines and inhibitors of deoxyuridylate synthesis. Biochem. Pharmacol. 31: 2929–2935, 1982.PubMedCrossRefGoogle Scholar
  37. 37.
    Moran RG, Werkheiser WC, Zakrzewski SF: Folate metabolism in mammalian cells in culture. I. Partial characterization of the folate derivatives present in L1210 mouse leukemia cells. J. Biol. Chem. 251: 3569–3575, 1976.Google Scholar
  38. 38.
    Houghton JA, Houghton PJ: On the mechanism of cytotoxicity of fluorinated pyrimidines on four human colon adenocarcinoma xenografts maintained in immune-deprived mice. Cancer 45: 1159–1167, 1980.PubMedCrossRefGoogle Scholar
  39. 39.
    Yin MB, Zakrzewski SF, Hakala MT: Relationship of cellular folate cofactor pools to activity of 5-FU. Mol. Pharmacol. 23: 190–197, 1983.PubMedGoogle Scholar
  40. 40.
    Evans RM, Laskin JD, Hakala MT: Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res. 41: 3288–3295, 1981.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1986

Authors and Affiliations

  • Peter V. Danenberg

There are no affiliations available

Personalised recommendations